These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

828 related items for PubMed ID: 26490356

  • 1. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M, Wang F, Zhao Y, Li S, Wang X, Shou T, Luo Y, Tang W.
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [Abstract] [Full Text] [Related]

  • 2. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT, Lee JS.
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [Abstract] [Full Text] [Related]

  • 3. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [Abstract] [Full Text] [Related]

  • 4. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, Tomii K, Katakami N.
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
    Baek JH, Sun JM, Min YJ, Cho EK, Cho BC, Kim JH, Ahn MJ, Park K.
    Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
    [Abstract] [Full Text] [Related]

  • 8. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.
    J Natl Cancer Inst; 2017 Jun 01; 109(6):. PubMed ID: 28376144
    [Abstract] [Full Text] [Related]

  • 9. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
    Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R, CLICaP.
    Lung Cancer; 2015 Feb 01; 87(2):169-75. PubMed ID: 25558790
    [Abstract] [Full Text] [Related]

  • 10. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM.
    Lung Cancer; 2017 Feb 01; 104():58-64. PubMed ID: 28213001
    [Abstract] [Full Text] [Related]

  • 11. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R, Spanish Lung Cancer Group.
    JAMA Oncol; 2015 May 01; 1(2):149-57. PubMed ID: 26181014
    [Abstract] [Full Text] [Related]

  • 12. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
    Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S.
    Lung Cancer; 2016 May 01; 95():73-81. PubMed ID: 27040855
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C.
    J Oncol Pharm Pract; 2016 Jun 01; 22(3):461-76. PubMed ID: 25855240
    [Abstract] [Full Text] [Related]

  • 14. Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
    Koyama N, Watanabe Y, Iwai Y, Kawamura R, Miwa C, Nagai Y, Hagiwara K, Koyama S.
    Chemotherapy; 2017 Jun 01; 62(3):151-158. PubMed ID: 28110331
    [Abstract] [Full Text] [Related]

  • 15. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K, Yu X, Wang H, Huang Z, Xu Y, Gong L, Fan Y.
    Cancer Chemother Pharmacol; 2017 Dec 01; 80(6):1179-1187. PubMed ID: 29063948
    [Abstract] [Full Text] [Related]

  • 16. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, Pan H, Yang X, Xie S, Feng X, Lv Z, Wang Y, Chen Z, He J.
    World J Surg Oncol; 2017 Nov 06; 15(1):197. PubMed ID: 29110716
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS.
    JAMA; 2014 Apr 09; 311(14):1430-7. PubMed ID: 24715074
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
    Liu JJ, Zhang S, Wu CJ, Ma LX, Liu Y, Li H, Cui HX, Cheng Y.
    Zhonghua Zhong Liu Za Zhi; 2016 Mar 23; 38(3):211-7. PubMed ID: 26988828
    [Abstract] [Full Text] [Related]

  • 20. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z, Zhang Y.
    Am J Clin Oncol; 2017 Aug 23; 40(4):362-369. PubMed ID: 25647830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.